What Is a 503B Outsourcing Facility?

What Section 503B is

Section 503B is a part of the Federal Food, Drug, and Cosmetic (FD&C) Act that defines a special kind of compounder called an outsourcing facility. It was added by the Drug Quality and Security Act of 2013 (DQSA), the same law that formalized traditional pharmacy compounding under Section 503A. Where 503A governs a pharmacist preparing a medication for one identified patient, 503B was designed for a middle ground between that pharmacy work and full drug manufacturing.

The core idea is scale with accountability. A 503B outsourcing facility can produce compounded preparations in larger batches, and it does not need a patient-specific prescription for each unit it makes — a hospital, for example, can stock standardized compounded doses from a 503B facility. In exchange for that flexibility, the facility accepts a much heavier set of federal obligations, starting with registration and inspection by the FDA.

How 503B works: cGMP and the bulks rule

Two features define the 503B pathway. The first is current good manufacturing practice (cGMP) — the same broad quality framework that governs commercial drug manufacturers. cGMP covers everything from facility design and environmental monitoring to batch records, stability testing, and release criteria. This is a substantially higher and more expensive standard than the state pharmacy-practice rules that apply to a 503A pharmacy.

The second feature is the bulk drug substance rule. A 503B facility may generally compound from a bulk substance — the raw active pharmaceutical ingredient — only when there is a documented clinical need and the substance appears on the FDA's dedicated 503B bulks list, or when the facility is compounding to address a drug shortage. This is a distinct list from the 503A bulks list, and it is generally narrower.

What a 503B facility must do

1. Register with the FDA as an outsourcing facility and submit to FDA inspection.
2. Comply with federal cGMP standards for its facility, processes, and testing.
3. Report adverse events and submit periodic product-reporting to the FDA.
4. Compound bulk substances only when there is a clinical need and the substance is on the 503B bulks list, or to address a shortage.
5. Label products and follow the specific conditions Section 503B sets out.

503B vs 503A — and why peptides still don't qualify

It is easy to assume that because a 503B facility is bigger and more heavily regulated, it can make things a 503A pharmacy cannot. For quality and scale, that is true — but for which bulk substances are allowed, 503B is actually the narrower gate. A 503A pharmacy has three possible sourcing paths (a USP monograph, being a component of an approved drug, or the 503A bulks list); a 503B facility is largely limited to the 503B bulks list plus the shortage exception.

That is why the outsourcing-facility route does not rescue research peptides. A substance like TB-500 (thymosin beta-4) is not on the 503B bulks list and is not a shortage drug, so a 503B facility cannot lawfully supply it — the same conclusion reached, for different technical reasons, at the 503A level. We work through that specific case in can pharmacies compound TB-500?, and the scientific background lives in the TB-500 research profile.

Decisions about which substances belong on either bulks list are informed by the FDA's advisory process, including the Pharmacy Compounding Advisory Committee (PCAC). If you are studying peptide handling for research purposes, our neutral reconstitution guide and dosing calculator explain the methodology behind the literature.